Yang, Lan, and Aixia Ma. “Cost-Utilities Analysis of Polatuzumab Vedotin Combined With Bendamustine and Rituximab for Relapsed Refractory Diffuse Large B-Cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation”. Frontiers in Business, Economics and Management, vol. 8, no. 3, Apr. 2023, pp. 178-84, https://doi.org/10.54097/fbem.v8i3.7835.